<p>Geode Capital Management LLC 在最近向证券交易委员会提交的文件中表示，在第二季度减少了对 Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - 免费报告) TSE: AUP 的持股比例，减少幅度为 9.1%。该公司在此期间出售了 157,240 股后，持有生物技术公司 1,577,060 股股票。Geode Capital Management LLC 在最近的报告期末持有 Aurinia Pharmaceuticals 约 1.20% 的股份，价值 13,355,000 美元。</p>
<ul>
<li>这两只医疗保健股票在 2023 年翻了一番</li>
</ul>
<p>其他一些对冲基金最近也买卖了 AUPH 的股票。MAI Capital Management 在第一季度以约 39,000 美元的价格获得了 Aurinia Pharmaceuticals 的新头寸。Mackenzie Financial Corp 在第一季度以约 86,000 美元的价格获得了 Aurinia Pharmaceuticals 的新头寸。Vanguard Personalized Indexing Management LLC 在第二季度以约 92,000 美元的价格购买了 Aurinia Pharmaceuticals 的新头寸。Teza Capital Management LLC 在第一季度以 96,000 美元的价格获得了 Aurinia Pharmaceuticals 的新股份。最后，Martingale Asset Management L P 在第一季度以 99,000 美元的价格获得了 Aurinia Pharmaceuticals 的新股份。36.83% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>分析师评级调整</h2>
<p>一些研究分析师最近对 AUPH 股票发表了看法。Bloom Burton 在 11 月 5 日星期三的报告中将 Aurinia Pharmaceuticals 的评级从 “适度买入” 下调至 “持有”。Jefferies Financial Group 在 11 月 7 日星期五的研究报告中将 Aurinia Pharmaceuticals 的评级从 “持有” 上调至 “买入”，并将该股票的目标价从 10.00 美元提高至 21.00 美元。加拿大皇家银行在 11 月 5 日星期三的报告中重申了 “行业表现” 评级，并将 Aurinia Pharmaceuticals 的目标价设定为 15.00 美元（之前为 9.00 美元）。最后，Weiss Ratings 在 10 月 8 日星期三的研究报告中重新发布了 Aurinia Pharmaceuticals 的 “持有 (c)” 评级。有两位分析师对该股票给予了买入评级，三位分析师对该公司的股票给予了持有评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “持有”，共识目标价为 17.67 美元。</p>
<p><strong>获取我们关于 Aurinia Pharmaceuticals 的最新报告</strong></p>
<h2>Aurinia Pharmaceuticals 股票表现</h2>
<p>NASDAQ AUPH 的股票在周二开盘价为 16.17 美元。该公司的债务与股本比率为 0.18，流动比率为 5.23，速动比率为 4.63。Aurinia Pharmaceuticals Inc 的一年低点为 6.55 美元，一年高点为 16.48 美元。该公司的 50 日移动平均价格为 13.31 美元，200 日移动平均价格为 11.05 美元。该公司的市值为 21.3 亿美元，市盈率为 37.61，贝塔值为 1.30。</p>
<p>Aurinia Pharmaceuticals (NASDAQ:AUPH - 获取免费报告) TSE: AUP 最近在 11 月 4 日星期二公布了季度财报。这家生物技术公司报告的每股收益 (EPS) 为 0.23 美元，超过了共识预期的 0.16 美元，超出幅度为 0.07 美元。Aurinia Pharmaceuticals 的股本回报率为 20.06%，净利润率为 23.31%。该公司在本季度的收入为 7347 万美元，而分析师预期为 6770 万美元。Aurinia Pharmaceuticals 已设定其 2025 财年的每股收益指导目标。分析师预计 Aurinia Pharmaceuticals Inc 本财年的每股收益将为 0.11 美元。</p>
<h2>Aurinia Pharmaceuticals 公司简介</h2>
<p>(免费报告)</p>
<p>Aurinia Pharmaceuticals Inc 是一家商业阶段的生物制药公司，专注于开发和商业化治疗美国各种未满足医疗需求疾病的疗法。它提供 LUPKYNIS 用于治疗活动性狼疮性肾炎的成年患者。它与大冢制药株式会社签订了合作和许可协议。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，而不是 Aurinia Pharmaceuticals</li>
<li>公用事业股票解析 - 如何以及为何投资公用事业</li>
<li>预计在 2025 年上涨超过 20%，这三只股票正在提升回购能力</li>
<li>这些液化天然气股票准备迎来反弹吗？</li>
<li>国会再次超越市场——这是他们购买的三只股票</li>
<li>成长股：它们是什么，示例以及如何投资</li>
<li>与三只顶级零售 ETF 一起进行购物狂欢</li>
</ul>
<p><strong>想看看其他对冲基金持有的 AUPH 股票吗？</strong> 访问 HoldingsChannel.com 获取 Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - 免费报告) TSE: AUP 的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVVQSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVVQSA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Aurinia Pharmaceuticals 吗？</h2>
<p>在考虑 Aurinia Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Aurinia Pharmaceuticals 并不在名单上。</p>
<p>虽然 Aurinia Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Aurinia制药

<p>Geode Capital Management LLC 在第二季度减少了对 Aurinia Pharmaceuticals Inc 的持股比例，下降了 9.1%，目前持有 1,577,060 股，价值 1,335 万美元。其他对冲基金也调整了在 AUPH 的持仓。分析师对该股票的评级意见不一，普遍维持 “持有” 评级，目标价为 17.67 美元。Aurinia 第三季度的收益超出预期，报告每股收益为 0.23 美元，营收为 7347 万美元</p>

<p>Geode Capital Management LLC lessened its stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 9.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,577,060 shares of the biotechnology company's stock after selling 157,240 shares during the period. Geode Capital Management LLC owned about 1.20% of Aurinia Pharmaceuticals worth $13,355,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Geode Capital Management LLC 在最近向证券交易委员会提交的文件中表示，在第二季度减少了对 Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - 免费报告) TSE: AUP 的持股比例，减少幅度为 9.1%。该公司在此期间出售了 157,240 股后，持有生物技术公司 1,577,060 股股票。Geode Capital Management LLC 在最近的报告期末持有 Aurinia Pharmaceuticals 约 1.20% 的股份，价值 13,355,000 美元。</p>
</div><ul>
<li>These 2 Healthcare Stocks Have Doubled in 2023</li>
</ul>
<div class="lb-trans"><ul>
<li>这两只医疗保健股票在 2023 年翻了一番</li>
</ul>
</div><p>A number of other hedge funds also recently bought and sold shares of AUPH. MAI Capital Management acquired a new position in shares of Aurinia Pharmaceuticals in the first quarter worth about $39,000. Mackenzie Financial Corp acquired a new position in Aurinia Pharmaceuticals in the 1st quarter worth approximately $86,000. Vanguard Personalized Indexing Management LLC purchased a new position in Aurinia Pharmaceuticals during the 2nd quarter worth approximately $92,000. Teza Capital Management LLC acquired a new stake in Aurinia Pharmaceuticals during the 1st quarter valued at $96,000. Finally, Martingale Asset Management L P acquired a new stake in Aurinia Pharmaceuticals during the 1st quarter valued at $99,000. 36.83% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金最近也买卖了 AUPH 的股票。MAI Capital Management 在第一季度以约 39,000 美元的价格获得了 Aurinia Pharmaceuticals 的新头寸。Mackenzie Financial Corp 在第一季度以约 86,000 美元的价格获得了 Aurinia Pharmaceuticals 的新头寸。Vanguard Personalized Indexing Management LLC 在第二季度以约 92,000 美元的价格购买了 Aurinia Pharmaceuticals 的新头寸。Teza Capital Management LLC 在第一季度以 96,000 美元的价格获得了 Aurinia Pharmaceuticals 的新股份。最后，Martingale Asset Management L P 在第一季度以 99,000 美元的价格获得了 Aurinia Pharmaceuticals 的新股份。36.83% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>A number of research analysts have recently weighed in on AUPH shares. Bloom Burton downgraded Aurinia Pharmaceuticals from a &#34;moderate buy&#34; rating to a &#34;hold&#34; rating in a report on Wednesday, November 5th. Jefferies Financial Group upgraded Aurinia Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating and raised their price objective for the stock from $10.00 to $21.00 in a research report on Friday, November 7th. Royal Bank Of Canada reiterated a &#34;sector perform&#34; rating and issued a $15.00 target price (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a report on Wednesday, November 5th. Finally, Weiss Ratings reissued a &#34;hold (c)&#34; rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $17.67.</p>
<div class="lb-trans"><p>一些研究分析师最近对 AUPH 股票发表了看法。Bloom Burton 在 11 月 5 日星期三的报告中将 Aurinia Pharmaceuticals 的评级从 “适度买入” 下调至 “持有”。Jefferies Financial Group 在 11 月 7 日星期五的研究报告中将 Aurinia Pharmaceuticals 的评级从 “持有” 上调至 “买入”，并将该股票的目标价从 10.00 美元提高至 21.00 美元。加拿大皇家银行在 11 月 5 日星期三的报告中重申了 “行业表现” 评级，并将 Aurinia Pharmaceuticals 的目标价设定为 15.00 美元（之前为 9.00 美元）。最后，Weiss Ratings 在 10 月 8 日星期三的研究报告中重新发布了 Aurinia Pharmaceuticals 的 “持有 (c)” 评级。有两位分析师对该股票给予了买入评级，三位分析师对该公司的股票给予了持有评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “持有”，共识目标价为 17.67 美元。</p>
</div><p><strong>Get Our Latest Report on Aurinia Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Aurinia Pharmaceuticals 的最新报告</strong></p>
</div><h2>Aurinia Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Aurinia Pharmaceuticals 股票表现</h2>
</div><p>Shares of NASDAQ AUPH opened at $16.17 on Tuesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63. Aurinia Pharmaceuticals Inc has a one year low of $6.55 and a one year high of $16.48. The business's 50-day moving average price is $13.31 and its two-hundred day moving average price is $11.05. The company has a market capitalization of $2.13 billion, a P/E ratio of 37.61 and a beta of 1.30.</p>
<div class="lb-trans"><p>NASDAQ AUPH 的股票在周二开盘价为 16.17 美元。该公司的债务与股本比率为 0.18，流动比率为 5.23，速动比率为 4.63。Aurinia Pharmaceuticals Inc 的一年低点为 6.55 美元，一年高点为 16.48 美元。该公司的 50 日移动平均价格为 13.31 美元，200 日移动平均价格为 11.05 美元。该公司的市值为 21.3 亿美元，市盈率为 37.61，贝塔值为 1.30。</p>
</div><p>Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.07. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%.The business had revenue of $73.47 million during the quarter, compared to analyst estimates of $67.70 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Aurinia Pharmaceuticals (NASDAQ:AUPH - 获取免费报告) TSE: AUP 最近在 11 月 4 日星期二公布了季度财报。这家生物技术公司报告的每股收益 (EPS) 为 0.23 美元，超过了共识预期的 0.16 美元，超出幅度为 0.07 美元。Aurinia Pharmaceuticals 的股本回报率为 20.06%，净利润率为 23.31%。该公司在本季度的收入为 7347 万美元，而分析师预期为 6770 万美元。Aurinia Pharmaceuticals 已设定其 2025 财年的每股收益指导目标。分析师预计 Aurinia Pharmaceuticals Inc 本财年的每股收益将为 0.11 美元。</p>
</div><h2>Aurinia Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Aurinia Pharmaceuticals 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.</p>
<div class="lb-trans"><p>Aurinia Pharmaceuticals Inc 是一家商业阶段的生物制药公司，专注于开发和商业化治疗美国各种未满足医疗需求疾病的疗法。它提供 LUPKYNIS 用于治疗活动性狼疮性肾炎的成年患者。它与大冢制药株式会社签订了合作和许可协议。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Aurinia Pharmaceuticals</li>
<li>Utilities Stocks Explained – How and Why to Invest in Utilities</li>
<li>Up Over 20% in 2025, These 3 Stocks Are Boosting Buyback Capacity</li>
<li>Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?</li>
<li>Congress Beat the Market Again—Here Are the 3 Stocks They Bought</li>
<li>Growth Stocks: What They Are, Examples and How to Invest</li>
<li>Go on a Shopping Spree With 3 Top Retail ETFs</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，而不是 Aurinia Pharmaceuticals</li>
<li>公用事业股票解析 - 如何以及为何投资公用事业</li>
<li>预计在 2025 年上涨超过 20%，这三只股票正在提升回购能力</li>
<li>这些液化天然气股票准备迎来反弹吗？</li>
<li>国会再次超越市场——这是他们购买的三只股票</li>
<li>成长股：它们是什么，示例以及如何投资</li>
<li>与三只顶级零售 ETF 一起进行购物狂欢</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding AUPH?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP.</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 AUPH 股票吗？</strong> 访问 HoldingsChannel.com 获取 Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - 免费报告) TSE: AUP 的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVVQSA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AUPH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aurinia Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Aurinia Pharmaceuticals 吗？</h2>
</div><p>Before you consider Aurinia Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Aurinia Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Aurinia Pharmaceuticals 并不在名单上。</p>
</div><p>While Aurinia Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Aurinia Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Geode Capital Management LLC 减持了其在 Aurinia 制药公司 $AUPH 的股份